Press Releases Roche Holding AG

Equities

ROG

CH0012032048

Market Closed - Swiss Exchange Other stock markets 16:31:59 30/04/2024 BST			5-day change	1st Jan Change
220.6 ^CHF	-0.27%		-2.30%	-9.78%

04-29	Swiss Equities Close in Red Amid Inflation Spotlight	MT
04-29	Roche Holding AG: slimming down

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer	04-18	BU
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS	04-17	BU
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study	04-15	BU
Invitation to Roche's First Quarter Sales 2024 Presentation	03-25	AQ
Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024	03-12	AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure	03-06	AQ
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies	02-25	BU
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	02-19	AQ
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies	02-16	BU
AlzeCure Pharma broadcasts live expert event on Alzheimer's around highly current gamma-secretase modulators	02-12	AQ
New long-term data for Roche's Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)	02-01	AQ
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)	02-01	BU
Prolight`s CEO to BioStock: "Roche's acquisition highlights interest in Point-of-Care"	01-29	AQ
Reminder, Invitation to Roche's Full Year Results 2023 Presentation	01-26	AQ
LINEAGE CELL - RG6501 PHASE 1/2A RESULTS WILL BE FEATURED AT 2024 ANGIOGENESIS EXUDATION AND DEGENERATION MEETING IN PRESENTATION BY ALLEN HO, MD, FACS, FASRS	01-17	AQ
Roche cancer immunotherapy receives new EU approval	01-16	AQ
Inotrem successfully reaches agreement with the FDA for a Phase 3 registration trial for nangibotide in septic shock	01-09	AQ
U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV Technology Patent Infringement Lawsuit	01-09	AQ
Stocks Commence 2024 Bullish Rally: LMDX, HNRC, BULT, HALB, SPZI	01-08	AQ
Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform	01-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 04:50 pm

Obesity: Roche joins the battle

December 04, 2023 at 03:48 pm